Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript

Diane Weiser
Senior Vice President of Corporate Affairs

Hello, everyone. I’m Diane Weiser, Senior Vice President of Corporate Affairs. I’m pleased to welcome everyone to our investor event to discuss the primary results from ACACIA-HCM, the pivotal Phase III clinical trial of aficamten in nonobstructive HCM. Today’s event is being hosted in a hybrid fashion. I’d like to welcome those here in the room with us in Munich as well as those joining online.

I’m pleased to introduce from Cytokinetics, Dr. Fady Malik, Steve Heitner and Robert Blum. And I’m also thrilled to welcome 3 leading experts in HCM for our panel discussions today, Dr. Martin Maron, Dr. Ahmad Masri and Dr. Christina Paitazoglou. Today’s agenda will begin with — is it on the slide? Today’s — we’re going to pause for a minute. Turning to today’s agenda. Fady Malik will provide some brief opening remarks. Next, Dr. Masri and Maron will provide an encore presentation of the ACACIA-HCM results that were presented earlier today in the hotline session at the Congress.

Then Steve will facilitate a panel discussion and Q&A session. And finally, Robert Blum will close us out providing some remarks. For those online, today’s slides are available for download in the webcast. You can submit questions to the panel at any point